EU encourages marketing of orphan products:
This article was originally published in Clinica
Executive Summary
The European Parliament has approved the EC regulation on orphan medicinal products, giving exclusive marketing rights for 10 years to products that would be unlikely to generate sufficient returns without such incentives. The regulation will cover products that diagnose, prevent or treat, life-threatening, seriously debilitating or serious chronic conditions and will include some products on the drug/device borderline, such as contrast media. Orphan status will be decided by a new committee set up at the European Medicines Evaluation Agency and companies will benefit from a range of incentives, including a reduction in, or a waiver of, registration fees.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.